Durata Therapeutics Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012

Update: Dalvance (dalbavancin) Now FDA Approved - May 23, 2014

MORRISTOWN, N.J.--(BUSINESS WIRE)--Oct 4, 2012 - Durata Therapeutics (NASDAQ: DRTX) today announced that data from two clinical trials of its lead product candidate, dalbavancin, will be presented in two posters during the IDWeek conference in San Diego from October 17-21, 2012.

IDWeek is the first-ever combined meeting of four prestigious societies: the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).

Durata is presenting the data during the Novel Antimicrobial Agents session on Saturday, October 20, 12:30 – 2:00 p.m. PT in Halls F-H:

 

  • A Study to Assess Skin Lesion Measurement Techniques Related to Acute Bacterial Skin and Skin Structure Infections (Dunne, et al). Abstract Number: 36757. Presenting author: Michael Dunne, MD
  • The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae (Dunne, et al). Abstract Number: 36184. Presenting authors: Michael Dunne, MD and Laura Koeth

Durata will display the two posters from Thursday, October 18 at 9:30 a.m. until Saturday, October 20 at 6:00 p.m.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.

 

Contact: Media Relations Contact
White Oak Communications, Inc.
Jed Weiner, (847) 392-4186
jed.weiner@comcast.net
or
Investor Relations Contacts
Durata Therapeutics
Corey Fishman, (973) 993-4865
Chief Operating Officer and Chief Financial Officer
cfishman@duratatherapeutics.com
or
The Trout Group LLC
Lee M. Stern, (646) 378-2922
lstern@troutgroup.com
www.troutgroup.com

 

Posted: October 2012

View comments

Hide
(web5)